Federal contract award
HHSO10033015T
IGF::OT::IGF FOR OTHER FUNCTIONS
Award details
Obligations, current value and potential value describe different measures; they are never added together.
| Field | Reported value |
|---|---|
| Agency | Department of Health and Human Services |
| Office | BARDA - ASPR / DAAPPO / BARDA DCMA |
| NAICS | 325414 — Biological Product (except Diagnostic) Manufacturing |
| PSC | AN13 — HEALTH R&D SERVICES; HEALTH CARE SERVICES; EXPERIMENTAL DEVELOPMENT |
| Parent award / vehicle | HHSO100201100005I |
| Set-aside | NO SET ASIDE USED. |
| Pricing type | COST PLUS FIXED FEE |
| Obligations | $3.1M |
| Current contract value | $3.1M |
| Potential contract value / ceiling | $3.1M |
| Start date | Sep 3, 2014 |
| Current end date | Dec 31, 2017 |
| Potential end date | Jun 9, 2024 |
| Latest award activity | Sep 13, 2024 |
| Source loaded | Sep 26, 2026 |
Funding and modification history
Showing the latest 6 of 6 loaded transactions. Negative values are deobligations.
| Date | Modification | Obligation change | Description |
|---|---|---|---|
| Sep 13, 2024 | P00005 | $140.2K | COMPARISON OF THE LEVEL OF PROTECTION PROVIDED BY RAXIBACUMAB, ETI-204 (MAB), AND AIG (PAB) AGAINST LETHAL CHALLENGES OF B. ANTHRACIS. |
| Aug 23, 2022 | P00004 | $-15.7K | DEOB OF UDO EXPIRING FUNDS |
| Jun 16, 2016 | 3 | $939.0K | IGF::OT::IGF FOR OTHER FUNCTIONS |
| Mar 30, 2016 | 2 | $0 | IGF::OT::IGF FOR OTHER FUNCTIONS |
| Nov 18, 2015 | 1 | $0 | IGF::OT::IGF FOR OTHER FUNCTIONS |
| Sep 3, 2014 | 0 | $2.0M | IGF::OT::IGF FOR OTHER FUNCTIONS |
Research next steps
- Verify whether remaining options may extend performance beyond the current end date.
- Confirm the ordering vehicle and your eligibility or a qualified teaming route.
- Check the stated set-aside against the solicitation and current certifications.
- Review the award scope and buyer evidence before making a bid/no-bid decision.